Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 21, 2026

Alset AI Announces Full Commercial Launch of Lyken.AI

View original at finance.yahoo.com
Alset AI Announces Full Commercial Launch of Lyken.AI AI Business to Deliver End-to-End Services, Production-Grade Software, and Infrastructure to Solve Real Business Problems VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / Alset AI Ventures Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global AI market may exceed $500 billion in 2026

    80% confidence

  • We believe that we are positioned to begin generating revenue in the first half of 2026

    80% confidence

  • We are incredibly excited to bring Lyken.AI to full commercial availability

    80% confidence

  • This launch enables us to fully leverage our strong vendor ecosystem and valued partners to execute on our pipeline of opportunities

    80% confidence

  • Approximately 88% of organizations worldwide use AI in at least one business function

    80% confidence

  • Middle-market businesses in North America report near universal AI engagement

    80% confidence

  • Global AI market has a compound annual growth rate (CAGR) of over 30% from 2026 onward, specifically 30.6%

    80% confidence

  • Global AI market projected at USD 539.45 billion in 2026

    80% confidence

  • 78% of global companies have adopted AI technologies overall

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com